XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program

MPER-Targeting HIV-1 ProgramPositive

AI Analysis

Summary

Viva-Thera makes its public debut with an MPER-targeting HIV-1 program that achieved Preclinical Candidate (PCC) nomination in seven months using XtalPi's AI and automation platform. The program combines atomic-resolution structural data with AI-driven drug discovery across four therapeutic modalities for HIV prevention, treatment, and cure.

Outcome Details

Candidate Nomination (CAN) achieved in seven months using XtalPi's AI platform

Importance:5/10

Sentiment:

0.70

HIVdrug discoveryAI platformsmall moleculepublic debutMPER-TMD-CT

Related Companies

$STTK $TRAX

Read the original article

Published by PR Newswire Biotech on September 22, 2026 5:36 PM

Read Original